| D008666 |
Metalloendopeptidases |
ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. |
Metallo-Endoproteinases,Metalloendopeptidase |
|
| D011804 |
Quinolines |
|
|
|
| D004791 |
Enzyme Inhibitors |
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. |
Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000072198 |
ADAM17 Protein |
A disintegrin and metalloproteinase domain-containing protein that cleaves the membrane-bound precursor of TUMOR NECROSIS FACTOR-ALPHA to its mature form. It cleaves several other CELL SURFACE PROTEINS, including INTERLEUKIN-1 RECEPTOR TYPE II; TRANSFORMING GROWTH FACTOR ALPHA; L-SELECTIN; MUCIN-1; and AMYLOID BETA-PROTEIN PRECURSOR. It can also function as an activator of the Notch signaling pathway by mediating the cleavage of NOTCH RECEPTORS. |
ADAM-17,ADAM-17 Protein,CD156b Antigen,Disintegrin and Metalloproteinase Domain-Containing Protein 17,TACA (Enzyme),TACE (Enzyme),TNF-alpha Convertase,TNF-alpha Converting Enzyme,Tumor Necrosis Factor Alpha Convertase,Tumor Necrosis Factor-alpha Convertase,Tumor Necrosis Factor-alpha Converting Enzyme,ADAM 17 Protein,Antigen, CD156b,Convertase, TNF-alpha,Disintegrin and Metalloproteinase Domain Containing Protein 17,TNF alpha Convertase,TNF alpha Converting Enzyme,Tumor Necrosis Factor alpha Converting Enzyme |
|
| D000818 |
Animals |
Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. |
Animal,Metazoa,Animalia |
|
| D001172 |
Arthritis, Rheumatoid |
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. |
Rheumatoid Arthritis |
|
| D013678 |
Technology, Pharmaceutical |
The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients. |
Technology, Pharmacy,Pharmaceutic Technology,Pharmaceutical Technology,Pharmacy Technology,Technology, Pharmaceutic |
|
| D014409 |
Tumor Necrosis Factor-alpha |
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. |
Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha |
|
| D015212 |
Inflammatory Bowel Diseases |
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. |
Bowel Diseases, Inflammatory,Inflammatory Bowel Disease |
|